Immunome, Inc. (NASDAQ:IMNM) Forecasted to Post FY2023 Earnings of ($0.50) Per Share

Immunome, Inc. (NASDAQ:IMNMFree Report) – Leerink Partnrs issued their FY2023 earnings per share estimates for shares of Immunome in a note issued to investors on Monday, January 29th. Leerink Partnrs analyst A. Berens anticipates that the company will earn ($0.50) per share for the year. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Immunome’s current full-year earnings is ($1.21) per share. Leerink Partnrs also issued estimates for Immunome’s Q4 2023 earnings at ($0.25) EPS, Q1 2024 earnings at ($1.05) EPS, Q2 2024 earnings at ($0.12) EPS, Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.18) EPS, FY2024 earnings at ($1.50) EPS, FY2025 earnings at ($1.36) EPS and FY2026 earnings at ($1.44) EPS.

Other research analysts have also issued reports about the company. Wedbush increased their target price on Immunome from $12.00 to $19.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 23rd. SVB Leerink assumed coverage on Immunome in a research report on Monday. They issued an “outperform” rating and a $30.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $19.00.

Read Our Latest Analysis on Immunome

Immunome Stock Down 10.4 %

Shares of Immunome stock opened at $16.57 on Wednesday. Immunome has a fifty-two week low of $4.04 and a fifty-two week high of $19.49. The firm has a market cap of $708.04 million, a PE ratio of -9.15 and a beta of 1.53. The business’s fifty day moving average is $10.86 and its two-hundred day moving average is $8.77.

Immunome (NASDAQ:IMNMGet Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.36) earnings per share for the quarter. The business had revenue of $3.57 million during the quarter.

Institutional Investors Weigh In On Immunome

A number of hedge funds have recently bought and sold shares of the business. Point72 Asset Management L.P. bought a new stake in shares of Immunome in the second quarter worth $3,307,000. TD Asset Management Inc bought a new stake in shares of Immunome in the third quarter worth $1,063,000. Bank of Montreal Can bought a new stake in shares of Immunome in the second quarter worth $800,000. Cerity Partners LLC bought a new stake in shares of Immunome in the fourth quarter worth $656,000. Finally, Emfo LLC bought a new stake in shares of Immunome in the fourth quarter worth $633,000. Institutional investors and hedge funds own 37.76% of the company’s stock.

About Immunome

(Get Free Report)

Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

Recommended Stories

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.